Quantitative Systems Pharmacology: A Case for Disease Models

被引：48
|
作者：
Musante, C. J. [1 ]
Ramanujan, S. [2 ]
Schmidt, B. J. [3 ]
Ghobrial, O. G.
Lu, J. [4 ]
Heatherington, A. C. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA 02139 USA
[2] Genentech Inc, San Francisco, CA USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] AstraZeneca, Cambridge, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / 01期
关键词：
PHARMACEUTICAL-INDUSTRY; MONOCLONAL-ANTIBODIES; DRUG DEVELOPMENT; THERAPEUTICS; CHALLENGES; INNOVATION; DISCOVERY;
D O I：
10.1002/cpt.528
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
引用
收藏
页码：24 / 27
页数：4
相关论文
共 50 条
  • [21] A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation of in-vivo CRISPR-Cas therapy
    Desai, Devam A.
    Schmidt, Stephan
    Cristofoletti, Rodrigo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its pAIns and gAIns
    Folguera-Blasco, Nuria
    Boshier, Florencia A. T.
    Uatay, Aydar
    Pichardo-Almarza, Cesar
    Lai, Massimo
    Biasetti, Jacopo
    Dearden, Richard
    Gibbs, Megan
    Kimko, Holly
    FRONTIERS IN SYSTEMS BIOLOGY, 2024, 4
  • [23] Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy
    Nguyen, Hoa Q.
    Iskenderian, Andrea
    Ehmann, David
    Jasper, Paul
    Zhang, Zhiwei
    Rong, Haojing
    Welty, Devin
    Narayanan, Rangaraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 342 - 352
  • [24] Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer
    Bouhaddou, Mehdi
    Yu, Li J.
    Lunardi, Serena
    Stamatelos, Spyros K.
    Mack, Fiona
    Gallo, James M.
    Birtwistle, Marc R.
    Walz, Antje-Christine
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02): : 419 - 429
  • [25] Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why
    Stephanou, Angelique
    Fanchon, Eric
    Innominato, Pasquale F.
    Ballesta, Annabelle
    ACTA BIOTHEORETICA, 2018, 66 (04) : 345 - 365
  • [26] Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why
    Angélique Stéphanou
    Eric Fanchon
    Pasquale F. Innominato
    Annabelle Ballesta
    Acta Biotheoretica, 2018, 66 : 345 - 365
  • [27] Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
    Tabrizi, Mohammad
    Funelas, Cherryl
    Suria, Hamza
    AAPS JOURNAL, 2010, 12 (04): : 592 - 601
  • [28] Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
    Mohammad Tabrizi
    Cherryl Funelas
    Hamza Suria
    The AAPS Journal, 2010, 12 : 592 - 601
  • [29] Reinforcement learning for systems pharmacology-oriented and personalized drug design
    Tan, Ryan K.
    Liu, Yang
    Xie, Lei
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (08) : 849 - 863
  • [30] Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
    Joo Yeon Lee
    Jogarao V. S. Gobburu
    The AAPS Journal, 2011, 13 : 508 - 518
12345